CORRESP Filing
Coya Therapeutics, Inc.
Date: March 19, 2026 · CIK: 0001835022 · Accession: 0001193125-26-115931
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294315
Letter
Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-294315) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on March 20, 2026, or as soon as practicable thereafter. Please call Perry Laub of Lowenstein Sandler LLP at (212) 419-5914 to confirm the effectiveness of the Registration Statement or with any questions.
March 19, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
COYA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 19, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-294315) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on March 20, 2026, or as soon as practicable thereafter. Please call Perry Laub of Lowenstein Sandler LLP at (212) 419-5914 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, COYA THERAPEUTICS, INC. By: /s/ Arun Swaminathan Name: Arun Swaminathan Title: Chief Executive Officer (Principal Executive Officer)